Fmoc-N-Me-L-Asp(OMpe)-OH
Need Assistance?
  • US & Canada:
    +
  • UK: +

Fmoc-N-Me-L-Asp(OMpe)-OH

* Please kindly note that our products are not to be used for therapeutic purposes and cannot be sold to patients.

Category
Fmoc-Amino Acids
Catalog number
BAT-008519
Molecular Formula
C26H31NO6
Molecular Weight
453.53

Fmoc-N-Me-L-Asp(OMpe)-OH, a specialized amino acid derivative embraced in peptide synthesis and research, finds diverse applications in scientific endeavors.

Peptide Synthesis: In the realm of solid-phase peptide synthesis (SPPS), Fmoc-N-Me-L-Asp(OMpe)-OH shines with its protective groups that shield amino acid functional sites throughout chain elongation. Its utilization enables the meticulous incorporation of Aspartic acid residues into intricate peptides, a crucial step in crafting bioactive peptides and therapeutic proteins with precision.

Drug Design: Delving into the domain of drug design, Fmoc-N-Me-L-Asp(OMpe)-OH emerges as a key player in developing peptide-based drug candidates endowed with heightened stability and affinity. The N-methyl group’s presence enhances the pharmacokinetics and proteolysis resistance of resulting peptides, particularly valuable in creating peptide drugs tailored for highly specific molecular targets, ushering in new possibilities in therapeutic interventions.

Structural Biology: Within the intricate tapestry of structural biology, researchers harness Fmoc-N-Me-L-Asp(OMpe)-OH to unravel the mysteries of protein structure-function relationships. By incorporating this derivative into synthetic peptide sequences, scientists delve deep into the effects of side-chain modifications on protein folding and stability, shedding light on the fundamental principles governing protein architecture and dynamics.

Bioconjugation: The realm of bioconjugation techniques witnesses the strategic use of Fmoc-N-Me-L-Asp(OMpe)-OH in linking peptides to a myriad of molecules, ranging from fluorescent probes to drugs and other biomolecules. This application facilitates the exploration of peptide interactions and the development of targeted delivery systems, with protective groups ensuring the peptide’s integrity throughout the intricate processes of conjugation, paving the way for groundbreaking advancements in targeted therapeutics.

1. The aspartimide problem in Fmoc-based SPPS. Part II
M Mergler, F Dick, B Sax, C Stähelin, T Vorherr J Pept Sci. 2003 Aug;9(8):518-26. doi: 10.1002/psc.473.
The sequence dependence of base-catalysed aspartmide formation during Fmoc-based SPPS was systematically studied employing the peptide models H-Val-Lys-Asp-Xaa-Tyr-Ile-OH. The extent of formation of aspartimide and related by-products was determined by RP-HPLC. Considerable amounts of by-products were formed in the case of Xaa = Asp(OtBu), Arg(Pbf), Asn(Mtt), Cys(Acm) and unprotected Thr. Aspartimide formation could be diminished by incorporation of Asp(OMpe) or by employing milder methods for Fmoc cleavage, e.g. hexamethyleneimine/N-methylpyrrolidine/HOBt/NMP/DMSO 4:50:4:71:71 (v/v/w/v/v).
2. New t-butyl based aspartate protecting groups preventing aspartimide formation in Fmoc SPPS
Raymond Behrendt, Simon Huber, Roger Martí, Peter White J Pept Sci. 2015 Aug;21(8):680-7. doi: 10.1002/psc.2790. Epub 2015 Jun 15.
Obtaining homogenous aspartyl-containing peptides via Fmoc/tBu chemistry is often an insurmountable obstacle. A generic solution for this issue utilising an optimised side-chain protection strategy that minimises aspartimide formation would therefore be most desirable. To this end, we developed the following new derivatives: Fmoc-Asp(OEpe)-OH (Epe = 3-ethyl-3-pentyl), Fmoc-Asp(OPhp)-OH (Php = 4-n-propyl-4-heptyl) and Fmoc-Asp(OBno)-OH (Bno = 5-n-butyl-5-nonyl). We have compared their effectiveness against that of Fmoc-Asp(OtBu)-OH and Fmoc-Asp(OMpe)-OH in the well-established scorpion toxin II model peptide variants H-Val-Lys-Asp-Asn/Arg-Tyr-Ile-OH by treatments of the peptidyl resins with the Fmoc removal reagents containing piperidine and DBU at both room and elevated temperatures. The new derivatives proved to be extremely effective in minimising aspartimide by-products in each application.
3. The aspartimide problem in Fmoc-based SPPS. Part III
M Mergler, F Dick J Pept Sci. 2005 Oct;11(10):650-7. doi: 10.1002/psc.668.
A newly developed Fmoc-Asp derivative, Fmoc-Asp beta-(2,3,4-trimethyl-pent-3-yl) ester, has been tried in the Fmoc-based SPPS of H-Val-Lys-Asp-Xaa-Tyr-Ile-OH, a well-established peptide model for studying base-catalysed aspartimide formation. When synthesizing the hexapeptide incorporating Gly, Arg(Pbf), Asn(Mtt), Asp(OtBu) or Cys(Acm) for Xaa, considerable amounts of aspartimide-related by-products were to be expected. The Asp(3) beta-carboxy protecting group and the duration of exposure to bases were varied. By-product formation could be reduced by incorporation of the new Asp derivative more efficiently than by introducing the less bulky Asp(OMpe). Significant improvements were observed in cases of prolonged contact with piperidine or DBU. Both beta-carboxy protecting groups were superior to the standard Asp(OtBu) which was also included in this study, but the additional stabilization gained by our new protecting group was valuable especially in syntheses of long peptides or difficult sequences.
Online Inquiry
Inquiry Basket